Truist Securities Maintains Hold on Fresenius Medical Care, Raises Price Target to $23
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has maintained a Hold rating on Fresenius Medical Care (NYSE:FMS) while raising the price target from $22 to $23.
October 07, 2024 | 12:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities has maintained a Hold rating on Fresenius Medical Care and increased the price target from $22 to $23, indicating a slightly positive outlook.
The increase in the price target from $22 to $23 suggests a slightly positive outlook from Truist Securities, which could lead to a minor positive impact on the stock price. However, the Hold rating indicates that the stock is expected to perform in line with the market.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100